Chrysazin

Dantron

Clinical data
Routes of administration	Oral, rectal (enema)
ATC code	A06AB03 (WHO) A06AG03 (WHO)
Identifiers
IUPAC name 1,8-dihydroxyanthracene-9,10-dione
CAS Number	117-10-2 Y
PubChem CID	2950
DrugBank	DB04816 N
ChemSpider	2845 Y
UNII	Z4XE6IBF3V
KEGG	D07107 N
ChEBI	CHEBI:3682 N
ChEMBL	CHEMBL53418 N
NIAID ChemDB	001375
ECHA InfoCard	100.003.794
Chemical and physical data
Formula	C14H8O4
Molar mass	240.211 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2c1cccc(O)c1C(=O)c3c2cccc3O
InChI InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H N Key:QBPFLULOKWLNNW-UHFFFAOYSA-N N
NY (what is this?)

Dantron (INN), also known as chrysazin or 1,8-dihydroxyanthraquinone, is an organic substance, formally derived from anthraquinone by the replacement of two hydrogen atoms by hydroxyl groups (–OH). It is used in some countries as a stimulant laxative.

It should not be confused with ondansetron, an unrelated drug that was marketed in South Africa under the trade name "Dantron".

In the USA, dantron is not used because it is considered to be a carcinogen.

In the UK it is considered a possible carcinogen and so its licence is restricted to patients who already have a diagnosis of terminal cancer. It is mainly used in palliative care to counteract the constipating effects of opioids. Its British Approved Name was danthron, but it has now been changed to "dantron", the recommended International Nonproprietary Name.

Dantron has the notable side-effect of causing red-colored urine.